AI
By
Will Sanofi’s AI Ethics Revolution Trigger a $100 Billion Shift in Biopharma and Medtech? How the Company’s Transparency Drive is Reshaping Global Healthcare
Key Highlights: AI Ethics at Scale: Sanofi Sets Global Leadership StandardSanofi’s establishment of a dedicated AI Ethical Review…
Is Thermo Fisher’s $10B Q2 Surge the Inflection Point for AI-Powered Biopharma? How Will It Reshape the Life Sciences Landscape?
Key Highlights Financial Resilience and Strategic MarginsThermo Fisher Scientific’s Q2 2025 report showcases its fortress-like financial discipline. With…
Can IGC Pharma’s New AI Models Change Alzheimer’s Diagnosis and Drug Discovery for Millions?
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
Can Cedars-Sinai’s CS Connect Revolutionize Virtual Care? 42,000 Patients Served, AI Outperforms Doctors in 77% of Cases, K Health Partnership Sets New Standard
Key Takeaways: AI helping doctors focus on care, not paperworkCedars-Sinai launched CS Connect to improve access to care…
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks, reshaping competitive timelines…
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics and Transform Rare-Disease Innovation?
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
